Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alkaloid AD SkopjeXMAE:ALK -0.87%100 Equity-to-Asset is 0.59 as of Jun. 2026, which is 17% below its 10-year median of 0.71. GuruFocus rates XMAE:ALK with a GF Score™ of 100/100 and a GF Value™ of MKD27,266.07 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,008 Drug Manufacturers companies, Alkaloid AD Skopje ranks worse than 50.79% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Alkaloid AD Skopje's Total Stockholders Equity for the quarter that ended in Jun. 2026 was MKD15,229 Mil. Alkaloid AD Skopje's Total Assets for the quarter that ended in Jun. 2026 was MKD25,870 Mil.
Therefore, Alkaloid AD Skopje's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.59.
The historical rank and industry rank for Alkaloid AD Skopje's Equity-to-Asset or its related term are showing as below:
XMAE:ALK'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.59 Med: 0.71 Max: 0.8
Current: 0.59
During the past 13 years, the highest Equity to Asset Ratio of Alkaloid AD Skopje was 0.80. The lowest was 0.59. And the median was 0.71.
XMAE:ALK's Equity-to-Asset is ranked worse than 50.79% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs XMAE:ALK: 0.59
Alkaloid AD Skopje (XMAE:ALK) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Alkaloid AD Skopje Equity-to-Asset Related Terms
Alkaloid AD Skopje Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Alkaloid AD Skopje's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAE:ALK vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alkaloid AD Skopje's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkaloid AD Skopje Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkaloid AD Skopje's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Alkaloid AD Skopje's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Alkaloid AD Skopje's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkaloid AD Skopje (XMAE:ALK) has a Equity-to-Asset of 0.59 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Alkaloid AD Skopje and its competitors. This is 17% below median its historical median of 0.71. Over the past decade, Alkaloid AD Skopje's Equity-to-Asset has ranged from 0.59 to 0.80. According to the industry distribution chart, Alkaloid AD Skopje ranks #512 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 50.8%.
Is Alkaloid AD Skopje's Equity-to-Asset too high?
Alkaloid AD Skopje's current Equity-to-Asset of 0.59 is 17% below median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 0.80. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Alkaloid AD Skopje's value of 0.59 is 1.7% below this industry median. Based on the distribution chart, Alkaloid AD Skopje ranks #512 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alkaloid AD Skopje has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkaloid AD Skopje's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alkaloid AD Skopje ranks #512 out of 1008 companies for Equity-to-Asset. This places Alkaloid AD Skopje in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Alkaloid AD Skopje's value of 0.59 is 1.7% below this benchmark. Historically, Alkaloid AD Skopje's own Equity-to-Asset has ranged from 0.59 to 0.80 over the past decade. While the company's 10-year median is 0.71 vs. the industry median of 0.60, Alkaloid AD Skopje has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkaloid AD Skopje's current Equity-to-Asset of 0.59 is 1.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Alkaloid AD Skopje and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkaloid AD Skopje's current Equity-to-Asset is 0.59, which is 17% below median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkaloid AD Skopje stock overvalued right now?
Based on GuruFocus' analysis, Alkaloid AD Skopje (XMAE:ALK) is currently considered Modestly Undervalued. The stock's GF Value™ is MKD27,266.07, compared to a current price of MKD22,800.00 — trading 16.4% below its estimated fair value. The current Equity-to-Asset is 0.59, which is 17% below median its 10-year median of 0.71 and 1.7% below the Drug Manufacturers industry median of 0.60. Alkaloid AD Skopje's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Alkaloid AD Skopje (XMAE:ALK), the current Equity-to-Asset is 0.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkaloid AD Skopje (XMAE:ALK) Overvalued in 2026?
Based on GuruFocus' analysis, Alkaloid AD Skopje stock appears to be undervalued.
The current stock price of MKD22,800.00 is trading 16.4% below its estimated GF Value™ of MKD27,266.07.
GuruFocus considers Alkaloid AD Skopje to be Modestly Undervalued.
Key valuation signals for XMAE:ALK:
Equity-to-Asset: 0.59 (17% below median its 10-year median of 0.71)
GF Value™: MKD27,266.07 vs. price of MKD22,800.00 (16.4% below fair value)
Industry Position: 1.7% below the Drug Manufacturers median (#512 of 1008)
No single metric tells the full story. See the XMAE:ALK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals. It derives maximum revenue from Pharmaceuticals products segment.
100GF Score
Get the complete analysis for XMAE:ALK
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAE:ALK has been successfully added to your 
